A virus almost everyone carries
More than 9 in 10 adults have been infected with EBV. It often spreads through saliva, which is why it is nicknamed "the kissing virus."
Once it gets in, EBV never truly leaves. It hides inside certain immune cells called B cells and stays there for life, usually without causing harm.
But doctors have long noticed something strange. Almost every person with MS has signs of past EBV infection. And people who get a bad case of mono (caused by EBV) have a higher chance of developing MS years later.
Until now, scientists couldn't fully explain the link.
Why MS is so hard to treat
MS affects around 2.8 million people worldwide. It happens when the immune system attacks the protective coating around nerves in the brain and spine.
This damage can cause fatigue, numbness, vision problems, trouble walking, and more. Symptoms can come and go — or slowly get worse.
Today's treatments can slow MS down. But they don't stop it completely, and they don't work the same for everyone. Many patients still feel like their disease is a mystery.
The old view vs. the new view
For years, doctors believed MS was caused by a mix of bad luck, genes, and environment. EBV was on the list of suspects. But no one could prove how the virus did its damage.
But here's the twist. This new research suggests EBV isn't just a bystander. It may be an active player — working with a person's genes to push the immune system toward attacking itself.
In other words, EBV may not cause MS on its own. It may pull the trigger on a gun the genes already loaded.
How the virus flips the switch
Think of your immune system like a security team. B cells are the guards that remember past threats. T cells are the soldiers that attack invaders.
Normally, the guards only call in soldiers when there's real danger. But in people with certain genes, EBV seems to sneak inside the guards and start whispering false alarms.
The infected B cells then release signals — tiny chemical messages called cytokines — that wake up T cells. Those T cells may then mistakenly attack the body's own nerves.
It's like a mole inside the security team, sending bad intel that leads to friendly fire.
Inside the study
The researchers ran one of the largest studies of its kind. They looked at DNA from more than 617,000 people across different ancestries to find genes linked to EBV infection.
They found 39 genetic "hot spots" that raise EBV risk. Many of these same spots were already known to raise MS risk.
Then they zoomed in. Using a new tool that can spot EBV inside single cells, they examined 1,069 infected B cells from 38 people. This let them see, cell by cell, what the virus was doing.
What surprised the scientists
The infected B cells weren't just sitting quietly. They were active. They were changing the way memory B cells — the long-term "guards" — grow up and behave.
Even more striking, the infected cells were cranking up genes linked to both EBV and MS at the same time. That's a big clue that the virus and the disease share the same wiring.
This does not mean a cure for MS is coming tomorrow.
But it's the clearest picture yet of how EBV and genes may team up to start the disease.
Where this fits in the bigger picture
Researchers have been chasing the EBV-MS link for decades. A major 2022 study showed EBV infection came before MS in nearly every case. This new work takes the next step — showing the biology behind that link.
It adds weight to the idea that stopping EBV, or stopping what it does inside B cells, could one day stop MS before it starts.
Right now, this is still research. There's no EBV test that can predict MS, and no new MS treatment from this study.
If you have MS, or a family member does, keep working with your neurologist and stick to the treatment plan that works for you.
If you're healthy, there's no reason to panic about EBV. Most people who get it never develop MS.
But this work does give hope. Several companies are already testing EBV vaccines and antiviral drugs aimed at MS.
Honest limitations
This study is a preprint, meaning it has not yet gone through full peer review. The single-cell work looked at just 38 people, which is a small group. And finding genetic links doesn't prove cause and effect.
More research is needed before doctors can act on these findings.
The next steps are already in motion. Scientists are testing EBV vaccines to see if they can prevent MS in high-risk people.
Others are developing drugs that target infected B cells directly. Early trials are underway, but it will likely take years before any of this reaches patients.
Science moves slowly because safety matters. But for the first time, researchers feel they're chasing the right suspect — and they know where it hides.
